New combo therapy targets tough lung cancer
NCT ID NCT05595460
First seen Apr 28, 2026 · Last updated May 25, 2026 · Updated 5 times
Summary
This early-phase study tests a new drug called RYZ101 added to standard chemotherapy and immunotherapy for people with a specific type of advanced small cell lung cancer that has spread. The main goals are to find the best dose and check for side effects. About 21 adults who have not yet been treated will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Facility
Los Angeles, California, 90024, United States
-
Research Facility
San Francisco, California, 94158, United States
-
Research Facility
Jacksonville, Florida, 32224, United States
-
Research Facility
Miami, Florida, 33136, United States
-
Research Facility
Orlando, Florida, 32806, United States
-
Research Facility
Iowa City, Iowa, 52242, United States
-
Research Facility
Grand Rapids, Michigan, 49503, United States
-
Research Facility
Rochester, Minnesota, 55905, United States
-
Research Facility
St Louis, Missouri, 63130, United States
-
Research Facility
Omaha, Nebraska, 68130, United States
-
Research Facility
Salt Lake City, Utah, 84112, United States
-
Research Facility
San Juan, Puerto Rico, 00935, Puerto Rico
-
Reserach Facility
Lexington, Kentucky, 40536, United States
Conditions
Explore the condition pages connected to this study.